Tybourne Capital Management HK Ltd. Takes Position in Alumis Inc. $ALMS

Tybourne Capital Management HK Ltd. acquired a new stake in Alumis Inc. (NASDAQ:ALMS) during the 2nd quarter, Holdings Channel reports. The firm acquired 1,399,250 shares of the company’s stock, valued at approximately $4,198,000. Alumis comprises approximately 12.2% of Tybourne Capital Management HK Ltd.’s portfolio, making the stock its 4th largest position.

Several other large investors have also made changes to their positions in the business. Credit Industriel ET Commercial lifted its position in shares of Alumis by 178.8% in the second quarter. Credit Industriel ET Commercial now owns 387,002 shares of the company’s stock valued at $1,161,000 after acquiring an additional 248,202 shares in the last quarter. Blair William & Co. IL purchased a new position in shares of Alumis in the second quarter valued at about $200,000. Kera Capital Partners Inc. purchased a new position in shares of Alumis in the second quarter valued at about $32,000. Goldman Sachs Group Inc. lifted its position in shares of Alumis by 24.0% in the first quarter. Goldman Sachs Group Inc. now owns 61,645 shares of the company’s stock valued at $378,000 after acquiring an additional 11,949 shares in the last quarter. Finally, Rhumbline Advisers lifted its position in shares of Alumis by 21.7% in the first quarter. Rhumbline Advisers now owns 16,543 shares of the company’s stock valued at $102,000 after acquiring an additional 2,949 shares in the last quarter.

Alumis Price Performance

Shares of NASDAQ ALMS opened at $4.51 on Monday. The business’s 50 day moving average is $4.44 and its two-hundred day moving average is $4.23. Alumis Inc. has a 1-year low of $2.76 and a 1-year high of $13.00. The stock has a market capitalization of $469.31 million, a P/E ratio of -0.96 and a beta of -1.47.

Alumis (NASDAQ:ALMS) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of ($1.11) by ($0.06). The business had revenue of $2.67 million during the quarter, compared to the consensus estimate of $1.80 million. As a group, equities research analysts anticipate that Alumis Inc. will post -8.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Wall Street Zen upgraded Alumis from a “strong sell” rating to a “hold” rating in a research report on Saturday, August 16th. Wells Fargo & Company assumed coverage on Alumis in a research report on Friday, July 25th. They issued an “overweight” rating and a $17.00 target price on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alumis in a research report on Friday. Morgan Stanley decreased their target price on Alumis from $23.00 to $22.00 and set an “overweight” rating on the stock in a research report on Friday, August 15th. Finally, HC Wainwright reiterated a “buy” rating and issued a $14.00 target price on shares of Alumis in a research report on Thursday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Alumis has an average rating of “Moderate Buy” and an average price target of $20.17.

Alumis Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.